Prognostic significance of ERCC 1 expression in postoperative patients with gastric cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic significance of ERCC1 expression in resected non small cell lung carcinoma.

  2011cited by this paper
• Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy

  2011cited by this paper
• Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy.

  2010cited by this paper
• 7th Edition of the AJCC Cancer Staging Manual: Stomach

  2010cited by this paper
• DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

  2010cited by this paper
• Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.

  2010cited by this paper
• Gastric cancer

  2009cited by this paper
• First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure.

  2007cited by this paper
• Current status of excision repair cross complementing-group 1 (ERCC1) in cancer.

  2007cited by this paper
• Molecular mechanisms of resistance and toxicity associated with platinating agents.

  2007cited by this paper
• ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.

  2007cited by this paper
• Molecular mechanisms of mammalian global genome nucleotide excision repair.

  2006cited by this paper
• Nucleotide Excision Repair

  2006cited by this paper
• Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.

  2006cited by this paper
• Reduced hematopoietic reserves in DNA interstrand crosslink repair‐deficient Ercc1−/− mice

  2005cited by this paper
• High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer

  2005cited by this paper
• Excision repair cross complementing-group 1: gene expression and platinum resistance.

  2004cited by this paper
• Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

  2002cited by this paper
• ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

  2001cited by this paper
• Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.

  2000cited by this paper
• Mechanism of open complex and dual incision formation by human nucleotide excision repair factors

  1997cited by this paper
• Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning

  1993cited by this paper
• Co‐correction of the ERCC1, ERCC4 and xeroderma pigmentosum group F DNA repair defects in vitro.

  1993cited by this paper

• A Potential Asset of Proteasome Inhibitor Singly or Combined with Cisplatin Provides Inhibitory Effect on Human Gastric Cancer Cells

  2017cites this paper
• Effects of taxol resistance gene 1 expression on the chemosensitivity of SGC-7901 cells to oxaliplatin

  2016cites this paper
• Prognostic value of ERCC 1 and ERCC 2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy

  2015cites this paper